Research Article| Volume 6, ISSUE 4, P122-128, October 1988

Topical antiandrogens in the treatment of male-pattern baldness

  • Roger S. Rittmaster
    Address for correspondence: Roger S. Rittmaster, MD, Department of Medicine, Halifax Infirmary, 1335 Queen Street, Halifax, NS, B3J 2H6, Canada.
    From the Division of Endocrinology, Department of Medicine, Dalhousie University, Faculty of Medicine, Halifax, Nova Scotia Canada
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      Antiandrogen therapy for androgen-induced baldness is in its infancy. In men, because of side effects, topical antiandrogens appear to hold the most promise. Assessing changes in scalp hair growth may be difficult, however, and hirsutism provides a useful model for testing the efficacy of topical antiandrogens. Systemic administration of 5a-reductase inhibitors may also eventually prove to be helpful in the treatment of male-pattern baldness, but side effects and long-term risks are unknown. In women, systemic antiandrogens appear to be a reasonable option for therapy and produce a good subjective response. Further research is needed, however, ta document the long-term risks and efficacy of systemic antiandrogen therapy in women.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinics in Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hamilton JB
        Male hormone stimulation is prerequisite and an incitant in common baldness.
        Am J Anat. 1942; 71: 451-480
        • Ebling FJ
        Hair follicles and associated glands as androgen targets.
        Clin Endocrinol Metab. 1986; 15: 319-339
        • Price VH
        Testosterone metabolism in the skin.
        Arch dermatol. 1975; 111: 1496-1502
        • Cipriani R
        • Ruzza G
        • Foresta C
        • et al.
        Sex hormone-binding globulin and saliva testosterone levels in men with androgenetic alopecia.
        Br J dermatol. 1983; 109: 249-252
        • Bingham KD
        • Shaw DA
        The metabolism of testosterone by human male scalp skin.
        J Endocrinol. 1973; 57: 111-121
        • Schweikert HU
        • Wilson JD
        Regulation of human hair growth by steroid hormones: I. Testosterone metabolism in isolated hairs.
        J Clin Endocrinol Metab. 1974; 38: 811-819
        • Griffin JE
        • Leshin M
        • Wilson JD
        Androgen resistance syndromes.
        Am J Physiol. 1982; 243: E81-E87
        • Imperato-McGinley J
        • Peterson RE
        • Gautier T
        • et al.
        Male pseudohermaphroditism secondary to 5 alpha-reductase deficiency—a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity.
        J Steroid Biochem. 1979; 11: 637-645
        • Saenger P
        Steroid 5-alpha reductase deficiency.
        Pediatr Adolesc Endocrinol. 1981; 8: 156-170
        • Kasick JM
        • Bergfeld WF
        • Steck WD
        • et al.
        Adrenal androgenic female-pattern alopecia: sex hormones and the balding woman.
        Cleve Clin Q. 1983; 50: 111-122
        • Ludwig E
        Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex.
        Br J dermatol. 1977; 97: 247-254
        • Miller JA
        • Darley CR
        • Karkavitsas K
        • et al.
        Low sex-hormone binding globulin levels in young women with diffuse hair loss.
        Br J dermatol. 1982; 106: 331-336
        • Eil C
        • Edelson SK
        The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors.
        J Clin Endocrinol Metab. 1984; 59: 51-55
        • Loriaux DL
        Ann Intern Med. 1976; 85 (moderator): 630-636
        • Gamborg-Nielsen P
        Treatment of idiopathic hirsutism with spironolactone.
        Dermatologica. 1982; 165: 194-196
        • Aron-Brunetiere R
        Aspects of endocrinological treatment of hair diseases.
        in: Orfanos CE Montagna W Stuttgen G International Congress on Hair Research 1st, Hamburg, Germany 1979 Springer-Verlag, Berlin1981: 312-317
        • Tromovitch TA
        • Glogau RG
        • Stegman SJ
        Medical treatment of male pattern alopecia (androgenic alopecia).
        Head Neck Surg. 1985; 7: 336-339
        • Brooks JR
        Treatment of hirsutism with 5 alpha-reductase inhibitors.
        Clin Endocrinol Metab. 1986; 15: 391-405
        • Wenderoth UK
        • George FW
        • Wilson JD
        The effect of a 5 alpha-reductase inhibitor on androgen-mediated growth of the dog prostate.
        Endocrinology. 1983; 113: 569-573
        • Liang T
        • Heiss CE
        Inhibition of 5 alpha-reductase, receptor binding, and nuclear uptake of androgens in the prostate by a 4-methyl-4-aza-steroid.
        J Biol Chem. 1981; 256: 7998-8005
        • Rittmaster RS
        • Uno H
        • Povar ML
        • et al.
        The effects of N, N-diethyl-4-methyl-3-oxo-4-Aza-5α-androstane-17β-carboxamide, a 5 alpha-reductase inhibitor and antiandrogen, on the development of baldness in the stumptail macaque.
        J Clin Endocrinol Metab. 1987; 65: 188-193
        • Brigham PA
        • Cappas A
        • Uno H
        The stumptailed macaque as a model for androgenetic alopecia: effects of topical minoxidil analyzed by use of the folliculogram.
        Clin dermatol. 1988; 6: 177
        • Rittmaster RS
        • Loriaux DL
        Ann Intern Med. 1987; 106: 95-107
        • Vigersky RA
        • Mehlman I
        • Glass AR
        • et al.
        Treatment of hirsute women with cimetidine.
        N Engl J Med. 1980; 303: 1042
        • Chapman MG
        • Dowsett M
        • Dewhurst CJ
        • et al.
        Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism.
        Br J Obstet Gynaecol. 1985; 92: 983-985
        • Gumming DC
        • Yang JC
        • Rebar RW
        • et al.
        Treatment of hirsutism with spironolactone.
        JAMA. 1982; 247
        • Evron S
        • Shapiro G
        • Diamant YZ
        Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women.
        Fertil Steril. 1981; 36: 468-471
        • Lobo RA
        • Shoupe D
        • Serafini P
        • et al.
        The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.
        Fertil Steril. 1985; 43: 200-205
        • Messina M
        • Manieri C
        • Biffignandi P
        • et al.
        Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism.
        J Endocrinol Invest. 1983; 6: 23-27
        • Milewicz A
        • Silber D
        • Kirschner MA
        Therapeutic effects of spironolactone in polycystic ovary syndrome.
        Obstet Gynecol. 1983; 61: 429-432
        • Pittaway DE
        • Maxson WS
        • Wentz AC
        Spironolactone in combination drug therapy for unresponsive hirsutism.
        Fertil Steril. 1985; 43: 878-882
        • Shapiro G
        • Evron S
        A novel use of spironolactone: treatment of hirsutism.
        J Clin Endocrinol Metab. 1980; 51: 429-432
        • Gamborg-Nielsen P
        Treatment of moderate idiopathic hirsutism with a cream containing canrenone (an antiandrogen).
        Dermatologica. 1982; 165: 636-639
        • Bergfeld WF
        Diffuse hair loss in women.
        Cutis. 1978; 22: 190-195
        • Burke BM
        • Cunliffe WJ
        Oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia.
        BrJ dermatol. 1985; 112: 124-125
        • Dawber RPR
        • Sonnex T
        • Ralfs I
        Oral anti-androgen treatment of common baldness in women.
        Br J dermatol. 1982; 107 (Suppl.): 20